Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Source: Nasdaq GlobeNewswire / 02 Nov 2022 08:00:02   America/New_York